AI Article Synopsis
- Salivary duct carcinoma (SDC) is a rare and aggressive type of salivary gland cancer with limited treatment options available.
- SDC is known to overexpress androgen receptors, with some cases showing responsiveness to androgen blockade treatments.
- This report details the first documented case of SDC responding to abiraterone, highlighting the potential for using various androgen blockade therapies in treating SDC, similar to approaches used in prostate cancer.
Article Abstract
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy with limited evidence guiding standard treatment. SDC is known to overexpress the androgen receptor, with only a handful of cases reporting responses to androgen blockade. This report presents a case of SDC responding to multiple lines of androgen blockade, including a rapid response to abiraterone, a CYP17 inhibitor effective in prostate cancer. This case represents the first published report of SDC responding to abiraterone and illustrates that androgen receptor expressing SDC may be treated with multiple lines of androgen blockade, including newer agents such as abiraterone. This case suggests that SDC may continue to be androgen-dependent after progression on androgen deprivation, which is analogous to prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2015.0040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.
EMBO Mol Med
January 2025
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.
Aggressive prostate cancer (PCa) variants associated with androgen receptor signaling inhibitor (ARSI) resistance and metastasis remain poorly understood. Here, we identify the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic castration-resistant prostate cancer (CRPC). High PlexinD1 expression in human PCa is correlated with adverse clinical outcomes.
View Article and Find Full Text PDFInitial treatment and resource utilization among patients with metastatic-castration sensitive prostate cancer in Japan: a retrospective real-world study.
Jpn J Clin Oncol
December 2024
Market Access & Public Affairs, Bayer Yakuhin, Ltd., Osaka, Japan.
Objectives: The introduction of novel drugs for metastatic castration-sensitive prostate cancer has expanded treatment options for patients. Associated changes in healthcare resource utilization may have occurred in tandem, but nationwide information is limited. This study aimed to describe initial treatment patterns and healthcare resource utilization (including costs) for patients with metastatic castration-sensitive prostate cancer in routine clinical practice in Japan.
View Article and Find Full Text PDFMetabolic Dysfunction in Idiopathic Intracranial Hypertension: Current Theories and Updates.
Aging Dis
December 2024
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Idiopathic intracranial hypertension (IIH) is a disease characterized by increased intracranial pressure (ICP) without identifiable secondary causes. While the increased ICP is a critical diagnostic feature, the underlying pathophysiological mechanisms remain unclear. Previous theories have suggested cerebrospinal fluid (CSF) overproduction, impaired reabsorption, or circulatory obstruction as potential causes.
View Article and Find Full Text PDFAndrogen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer.
Cancer Discov
December 2024
Oregon Health & Science University, Portland, OR, United States.
Tumors escape immune detection and elimination through a variety of mechanisms. Here, we used prostate cancer as a model to examine how androgen-dependent tumors undergo immune evasion through downregulation of the major histocompatibility complex class I (MHCI). We report that response to immunotherapy in late-stage prostate cancer is associated with elevated MHC expression.
View Article and Find Full Text PDFVaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.
Vaccines (Basel)
November 2024
Department of Pathology, Duke University, Durham, NC 27710, USA.
: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target this axis, many of these fail due to the emergent expression of AR RNA splice variants, such as AR-V7, that can signal independently of ligand binding. Other therapies, such as vaccination against prostate-specific antigens, have achieved FDA approvals but have fallen short of being incorporated as standard-of-care therapies for advanced prostate cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!